Recruiting

VascTrac

Sponsor:

Palo Alto Veterans Institute for Research

Code:

NCT03048890

Conditions

Peripheral Artery Disease

Intermittent Claudication

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Physical activity levels

Study Details

Brief summary:

VascTrac is a mobile medical application that tracks users' physical activity levels in order to predict endovascular failure of patients with Peripheral Artery Disease.

Conditions

Peripheral Artery Disease

Intermittent Claudication

Study ID

NCT03048890

Start date

Mar 1, 2017

Status verified date

Nov, 2022

Completion date

Dec 1, 2023

Anticipated

Primary completion date

Dec 1, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • adult, has iPhone 5s, can read English

Exclusion Criteria:

  • under 18 years

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients with PAD

Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.

Patients without PAD

Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.

Interventions

Physical activity levels

Patients with severely low physical activity levels will be notified to consult their physician.

Primary outcome measure

  • Physical Activity [ Time Frame: Two Years ]

Central Contacts and Locations

Central contacts

Oliver O Aalami, MD

650-852-3451aalami@stanford.edu

Locations

VA Palo Alto Health Care System

Recruiting

Palo Alto, California, United States, 94304

Contacts

Oliver Aalami, MD

650-493-5000aalami@stanford.edu

More Information

Sponsor

Palo Alto Veterans Institute for Research

Last update posted

Nov 3, 2022

Last verified

Nov, 2022

Keywords

  • PAD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Palo Alto Veterans Institute for Research on 2022-11-03.